These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 32032568)
1. Analytical and biological assessment of circulating human erythroferrone. Appleby S; Chew-Harris J; Troughton RW; Richards AM; Pemberton CJ Clin Biochem; 2020 May; 79():41-47. PubMed ID: 32032568 [TBL] [Abstract][Full Text] [Related]
2. Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis. Honda H; Kobayashi Y; Onuma S; Shibagaki K; Yuza T; Hirao K; Yamamoto T; Tomosugi N; Shibata T PLoS One; 2016; 11(3):e0151601. PubMed ID: 26978524 [TBL] [Abstract][Full Text] [Related]
3. Differentiating iron-loading anemias using a newly developed and analytically validated ELISA for human serum erythroferrone. Diepeveen L; Roelofs R; Grebenchtchikov N; van Swelm R; Kautz L; Swinkels D PLoS One; 2021; 16(7):e0254851. PubMed ID: 34283879 [TBL] [Abstract][Full Text] [Related]
4. Marathon Run-induced Changes in the Erythropoietin-Erythroferrone-Hepcidin Axis are Iron Dependent. Tomczyk M; Kortas J; Flis D; Kaczorowska-Hac B; Grzybkowska A; Borkowska A; Lewicka E; Dabrowska-Kugacka A; Antosiewicz J Int J Environ Res Public Health; 2020 Apr; 17(8):. PubMed ID: 32316587 [TBL] [Abstract][Full Text] [Related]
5. Normal range and predictors of serum erythroferrone in infants. Bäckström F; Chmielewska A; Domellöf M; Berglund SK Pediatr Res; 2023 Sep; 94(3):965-970. PubMed ID: 37069224 [TBL] [Abstract][Full Text] [Related]
6. Immunoassay for human serum erythroferrone. Ganz T; Jung G; Naeim A; Ginzburg Y; Pakbaz Z; Walter PB; Kautz L; Nemeth E Blood; 2017 Sep; 130(10):1243-1246. PubMed ID: 28739636 [TBL] [Abstract][Full Text] [Related]
7. Erythroferrone as a sensitive biomarker to detect stimulation of erythropoiesis. Ramirez Cuevas K; Schobinger C; Gottardo E; Voss SC; Kuuranne T; Tissot JD; Favrat B; Townsend N; Leuenberger N Drug Test Anal; 2020 Feb; 12(2):261-267. PubMed ID: 31655016 [TBL] [Abstract][Full Text] [Related]
8. Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant. Pirotte M; Fillet M; Seidel L; Jaspers A; Baron F; Beguin Y Am J Hematol; 2021 Oct; 96(10):1275-1286. PubMed ID: 34310730 [TBL] [Abstract][Full Text] [Related]
9. Umbilical Cord Erythroferrone Is Inversely Associated with Hepcidin, but Does Not Capture the Most Variability in Iron Status of Neonates Born to Teens Carrying Singletons and Women Carrying Multiples. Delaney KM; Guillet R; Pressman EK; Ganz T; Nemeth E; O'Brien KO J Nutr; 2021 Sep; 151(9):2590-2600. PubMed ID: 34236433 [TBL] [Abstract][Full Text] [Related]
10. Effects of altitude and recombinant human erythropoietin on iron metabolism: a randomized controlled trial. Breenfeldt Andersen A; Bonne TC; Bejder J; Jung G; Ganz T; Nemeth E; Olsen NV; Huertas JR; Nordsborg NB Am J Physiol Regul Integr Comp Physiol; 2021 Aug; 321(2):R152-R161. PubMed ID: 34160288 [TBL] [Abstract][Full Text] [Related]
11. Erythroferrone, the new iron regulator: evaluation of its levels in Egyptian patients with beta thalassemia. El-Gamal RAE; Abdel-Messih IY; Habashy DM; Zaiema SEG; Pessar SA Ann Hematol; 2020 Jan; 99(1):31-39. PubMed ID: 31834456 [TBL] [Abstract][Full Text] [Related]
12. Hepcidin-25/erythroferrone ratio predicts improvement of anaemia in haemodialysis patients treated with ferric citrate hydrate. Hara M; Nakamura Y; Suzuki H; Asao R; Nakamura M; Nishida K; Kenmotsu S; Inagaki M; Tsuji M; Kiuchi Y; Ohsawa I; Goto Y; Gotoh H Nephrology (Carlton); 2019 Aug; 24(8):819-826. PubMed ID: 30239062 [TBL] [Abstract][Full Text] [Related]
13. Changes in the Serum Hepcidin-to-ferritin Ratio with Erythroferrone after Hepatitis C Virus Eradication Using Direct-acting Antiviral Agents. Inomata S; Anan A; Yamauchi E; Yamauchi R; Kunimoto H; Takata K; Tanaka T; Yokoyama K; Morihara D; Takeyama Y; Irie M; Shakado S; Sohda T; Sakisaka S Intern Med; 2019 Oct; 58(20):2915-2922. PubMed ID: 31243222 [TBL] [Abstract][Full Text] [Related]
14. The effect of erythroferrone suppression by transfusion on the erythropoietin-erythroferrone-hepcidin axis in transfusion-dependent thalassaemia: A pre-post cohort study. Zaman BA; Rasool SO; Abdo JM Br J Haematol; 2023 May; 201(3):547-551. PubMed ID: 36535905 [TBL] [Abstract][Full Text] [Related]
15. Is the erythropoietin-erythroferrone-hepcidin axis intact in human neonates? Bahr TM; Ward DM; Jia X; Ohls RK; German KR; Christensen RD Blood Cells Mol Dis; 2021 May; 88():102536. PubMed ID: 33450539 [TBL] [Abstract][Full Text] [Related]
16. Hepcidin as a potential biomarker for blood doping. Leuenberger N; Bulla E; Salamin O; Nicoli R; Robinson N; Baume N; Saugy M Drug Test Anal; 2017 Jul; 9(7):1093-1097. PubMed ID: 27758046 [TBL] [Abstract][Full Text] [Related]
17. Erythropoiesis and Iron Parameters in Transfusion-dependent and Nontransfusion-dependent Thalassemias. Ozturk Z; Gumuslu S; Yalcin K; Kupesiz A J Pediatr Hematol Oncol; 2021 Jul; 43(5):186-192. PubMed ID: 34157011 [TBL] [Abstract][Full Text] [Related]
18. Erythroferrone structure, function, and physiology: Iron homeostasis and beyond. Srole DN; Ganz T J Cell Physiol; 2021 Jul; 236(7):4888-4901. PubMed ID: 33372284 [TBL] [Abstract][Full Text] [Related]
19. The association between growth differentiation factor-15, erythroferrone, and iron status in thalassemic patients. Youssry I; Samy RM; AbdelMohsen M; Salama NM Pediatr Res; 2024 Mar; 95(4):1095-1100. PubMed ID: 37464096 [TBL] [Abstract][Full Text] [Related]
20. EPO-R+ myelodysplastic cells with ring sideroblasts produce high erythroferrone levels to reduce hepcidin expression in hepatic cells. Miura S; Kobune M; Horiguchi H; Kikuchi S; Iyama S; Murase K; Goto A; Ikeda H; Takada K; Miyanishi K; Kato J Blood Cells Mol Dis; 2019 Sep; 78():1-8. PubMed ID: 31082798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]